2상모집 예정

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

연구 개요

The current study is a follow-up to 2 previous parent studies, a dose-selection study with 3 different dose-levels of the altSonflex1-2-3 vaccine in a schedule of 3 vaccinations (H06\_01TP study \[NCT05073003, 212149\]) and a study with an alternate 2 vaccination schedule H06\_02TP study \[NCT06663436, 219449\]). The current study aims to assess the longevity of the immune response to the selected dose of the altSonflex1-2-3 vaccine 1, 2, and 3 years after the last vaccination in African children. The study involves no new vaccinations but will collect immunogenicity blood samples from participants.

스폰서
리드: GSK
적응증
Diarrhoea
중재
AltSonflex1-2-3, Menveo, Infanrix hexa, TYPHIBEV
목표 등록
528
시작일
2026-01-02
완료(예정)
2028-10-31

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.